25 XP   0   0   10

Guangdong Hybribio Biotech Co Ltd
Buy, Hold or Sell?

Let's analyse Hybribio together

PenkeI guess you are interested in Guangdong Hybribio Biotech Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Guangdong Hybribio Biotech Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Guangdong Hybribio Biotech Co Ltd

I send you an email if I find something interesting about Guangdong Hybribio Biotech Co Ltd.

Quick analysis of Hybribio (30 sec.)










What can you expect buying and holding a share of Hybribio? (30 sec.)

How much money do you get?

How much money do you get?
¥0.03
When do you have the money?
1 year
How often do you get paid?
84.2%

What is your share worth?

Current worth
¥7.94
Expected worth in 1 year
¥8.02
How sure are you?
94.7%

+ What do you gain per year?

Total Gains per Share
¥0.31
Return On Investment
4.9%

For what price can you sell your share?

Current Price per Share
¥6.26
Expected price per share
¥5.65 - ¥7.81
How sure are you?
50%

1. Valuation of Hybribio (5 min.)




Live pricePrice per Share (EOD)

¥6.26

Intrinsic Value Per Share

¥3.08 - ¥3.61

Total Value Per Share

¥11.03 - ¥11.56

2. Growth of Hybribio (5 min.)




Is Hybribio growing?

Current yearPrevious yearGrowGrow %
How rich?$712.2m$589.8m$127.1m17.7%

How much money is Hybribio making?

Current yearPrevious yearGrowGrow %
Making money$14.1m$58.4m-$44.3m-313.6%
Net Profit Margin19.6%33.8%--

How much money comes from the company's main activities?

3. Financial Health of Hybribio (5 min.)




4. Comparing to competitors in the Diagnostics & Research industry (5 min.)




  Industry Rankings (Diagnostics & Research)  


Richest
#40 / 145

Most Revenue
#25 / 145

Most Profit
#13 / 145

What can you expect buying and holding a share of Hybribio? (5 min.)

Welcome investor! Hybribio's management wants to use your money to grow the business. In return you get a share of Hybribio.

What can you expect buying and holding a share of Hybribio?

First you should know what it really means to hold a share of Hybribio. And how you can make/lose money.

Speculation

The Price per Share of Hybribio is ¥6.26. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Hybribio.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Hybribio, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥7.94. Based on the TTM, the Book Value Change Per Share is ¥0.02 per quarter. Based on the YOY, the Book Value Change Per Share is ¥0.74 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.06 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Hybribio.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.010.2%0.020.3%0.091.4%0.040.6%0.040.6%
Usd Book Value Change Per Share0.000.1%0.000.0%0.101.6%0.060.9%0.060.9%
Usd Dividend Per Share0.000.0%0.010.1%0.010.1%0.000.1%0.000.1%
Usd Total Gains Per Share0.000.1%0.010.2%0.111.7%0.061.0%0.061.0%
Usd Price Per Share1.34-1.86-3.51-3.59-3.59-
Price to Earnings Ratio32.02-28.59-11.69-55.33-55.33-
Price-to-Total Gains Ratio350.78-319.08-36.17--2,106.68--2,106.68-
Price to Book Ratio1.22-1.67-4.03-7.91-7.91-
Price-to-Total Gains Ratio350.78-319.08-36.17--2,106.68--2,106.68-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.864506
Number of shares1156
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.00
Usd Book Value Change Per Share0.000.06
Usd Total Gains Per Share0.010.06
Gains per Quarter (1156 shares)12.3471.69
Gains per Year (1156 shares)49.37286.77
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
138113920267277
276228840534564
31143413759801851
4153451867910681138
5191562359913351425
62296728411916021712
72677933313818691999
83059038215821362286
934310143117824032573
1038211248019826702860

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%19.00.00.0100.0%19.00.00.0100.0%19.00.00.0100.0%
Book Value Change Per Share3.01.00.075.0%11.01.00.091.7%17.02.00.089.5%17.02.00.089.5%17.02.00.089.5%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%16.00.03.084.2%16.00.03.084.2%16.00.03.084.2%
Total Gains per Share4.00.00.0100.0%12.00.00.0100.0%18.01.00.094.7%18.01.00.094.7%18.01.00.094.7%

Fundamentals of Hybribio

About Guangdong Hybribio Biotech Co Ltd

Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-time PCR kits and thalassemia genoarray diagnostic kits; hearing loss susceptibility genoarray diagnostic kits; COVID-19 real-time PCR kits; and devices/instruments, including automated nucleic acid extraction, automatic medical PCR analysis, flow-through hybridization, auto DNA extraction, and fluorescent quantitative detection systems, as well as after-sales technical service support. Its products are used in the fields of national screening, clinical, and research purposes. The company operates in the Asia Pacific, the South East Asia, the Middle East, Europe, Africa, and South America. The company was founded in 2003 and is based in Chaozhou, China.

Fundamental data was last updated by Penke on 2024-04-23 07:29:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Guangdong Hybribio Biotech Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Hybribio earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Hybribio to the Diagnostics & Research industry mean.
  • A Net Profit Margin of 20.2% means that ¥0.20 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Guangdong Hybribio Biotech Co Ltd:

  • The MRQ is 20.2%. The company is making a huge profit. +2
  • The TTM is 19.6%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ20.2%TTM19.6%+0.6%
TTM19.6%YOY33.8%-14.2%
TTM19.6%5Y25.7%-6.1%
5Y25.7%10Y25.7%0.0%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ20.2%-7.3%+27.5%
TTM19.6%-6.7%+26.3%
YOY33.8%-1.9%+35.7%
5Y25.7%-1.5%+27.2%
10Y25.7%-3.4%+29.1%
1.1.2. Return on Assets

Shows how efficient Hybribio is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Hybribio to the Diagnostics & Research industry mean.
  • 0.8% Return on Assets means that Hybribio generated ¥0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Guangdong Hybribio Biotech Co Ltd:

  • The MRQ is 0.8%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 1.6%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ0.8%TTM1.6%-0.8%
TTM1.6%YOY7.7%-6.1%
TTM1.6%5Y4.4%-2.8%
5Y4.4%10Y4.4%0.0%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8%-1.3%+2.1%
TTM1.6%-1.3%+2.9%
YOY7.7%-0.9%+8.6%
5Y4.4%-0.5%+4.9%
10Y4.4%-0.9%+5.3%
1.1.3. Return on Equity

Shows how efficient Hybribio is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Hybribio to the Diagnostics & Research industry mean.
  • 1.0% Return on Equity means Hybribio generated ¥0.01 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Guangdong Hybribio Biotech Co Ltd:

  • The MRQ is 1.0%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.1%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.0%TTM2.1%-1.1%
TTM2.1%YOY10.6%-8.5%
TTM2.1%5Y5.8%-3.7%
5Y5.8%10Y5.8%0.0%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0%-0.5%+1.5%
TTM2.1%0.2%+1.9%
YOY10.6%-0.3%+10.9%
5Y5.8%-1.4%+7.2%
10Y5.8%-2.3%+8.1%

1.2. Operating Efficiency of Guangdong Hybribio Biotech Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Hybribio is operating .

  • Measures how much profit Hybribio makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Hybribio to the Diagnostics & Research industry mean.
  • An Operating Margin of 0.0% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Guangdong Hybribio Biotech Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM16.2%-16.2%
TTM16.2%YOY44.2%-28.0%
TTM16.2%5Y30.0%-13.9%
5Y30.0%10Y30.0%0.0%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ--7.4%+7.4%
TTM16.2%0.5%+15.7%
YOY44.2%4.0%+40.2%
5Y30.0%3.7%+26.3%
10Y30.0%-1.3%+31.3%
1.2.2. Operating Ratio

Measures how efficient Hybribio is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • An Operation Ratio of 1.55 means that the operating costs are ¥1.55 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Guangdong Hybribio Biotech Co Ltd:

  • The MRQ is 1.546. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.168. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.546TTM1.168+0.378
TTM1.168YOY0.845+0.323
TTM1.1685Y0.972+0.196
5Y0.97210Y0.9720.000
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5461.280+0.266
TTM1.1681.304-0.136
YOY0.8451.236-0.391
5Y0.9721.242-0.270
10Y0.9721.205-0.233

1.3. Liquidity of Guangdong Hybribio Biotech Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Hybribio is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A Current Ratio of 4.57 means the company has ¥4.57 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Guangdong Hybribio Biotech Co Ltd:

  • The MRQ is 4.568. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.950. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.568TTM3.950+0.619
TTM3.950YOY3.370+0.580
TTM3.9505Y4.960-1.010
5Y4.96010Y4.9600.000
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ4.5682.122+2.446
TTM3.9502.298+1.652
YOY3.3702.599+0.771
5Y4.9603.012+1.948
10Y4.9603.081+1.879
1.3.2. Quick Ratio

Measures if Hybribio is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Hybribio to the Diagnostics & Research industry mean.
  • A Quick Ratio of 3.21 means the company can pay off ¥3.21 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Guangdong Hybribio Biotech Co Ltd:

  • The MRQ is 3.211. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.803. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.211TTM2.803+0.408
TTM2.803YOY2.506+0.297
TTM2.8035Y2.967-0.163
5Y2.96710Y2.9670.000
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ3.2111.230+1.981
TTM2.8031.345+1.458
YOY2.5061.661+0.845
5Y2.9671.957+1.010
10Y2.9672.295+0.672

1.4. Solvency of Guangdong Hybribio Biotech Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Hybribio assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Hybribio to Diagnostics & Research industry mean.
  • A Debt to Asset Ratio of 0.15 means that Hybribio assets are financed with 15.4% credit (debt) and the remaining percentage (100% - 15.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Guangdong Hybribio Biotech Co Ltd:

  • The MRQ is 0.154. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.183. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.154TTM0.183-0.029
TTM0.183YOY0.206-0.024
TTM0.1835Y0.153+0.030
5Y0.15310Y0.1530.000
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1540.429-0.275
TTM0.1830.407-0.224
YOY0.2060.394-0.188
5Y0.1530.448-0.295
10Y0.1530.446-0.293
1.4.2. Debt to Equity Ratio

Measures if Hybribio is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Hybribio to the Diagnostics & Research industry mean.
  • A Debt to Equity ratio of 19.2% means that company has ¥0.19 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Guangdong Hybribio Biotech Co Ltd:

  • The MRQ is 0.192. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.238. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.192TTM0.238-0.046
TTM0.238YOY0.284-0.045
TTM0.2385Y0.199+0.039
5Y0.19910Y0.1990.000
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1920.606-0.414
TTM0.2380.571-0.333
YOY0.2840.603-0.319
5Y0.1990.651-0.452
10Y0.1990.734-0.535

2. Market Valuation of Guangdong Hybribio Biotech Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Hybribio generates.

  • Above 15 is considered overpriced but always compare Hybribio to the Diagnostics & Research industry mean.
  • A PE ratio of 32.02 means the investor is paying ¥32.02 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Guangdong Hybribio Biotech Co Ltd:

  • The EOD is 20.624. Based on the earnings, the company is fair priced.
  • The MRQ is 32.023. Based on the earnings, the company is overpriced. -1
  • The TTM is 28.587. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD20.624MRQ32.023-11.399
MRQ32.023TTM28.587+3.436
TTM28.587YOY11.690+16.897
TTM28.5875Y55.331-26.744
5Y55.33110Y55.3310.000
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD20.624-0.254+20.878
MRQ32.023-0.395+32.418
TTM28.587-0.199+28.786
YOY11.690-0.008+11.698
5Y55.3313.483+51.848
10Y55.3314.432+50.899
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Guangdong Hybribio Biotech Co Ltd:

  • The EOD is 22.656. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 35.179. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is -1.763. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD22.656MRQ35.179-12.522
MRQ35.179TTM-1.763+36.942
TTM-1.763YOY-4.971+3.208
TTM-1.7635Y-459.624+457.861
5Y-459.62410Y-459.6240.000
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD22.656-0.315+22.971
MRQ35.179-0.441+35.620
TTM-1.763-1.388-0.375
YOY-4.971-2.175-2.796
5Y-459.624-1.665-457.959
10Y-459.624-1.971-457.653
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Hybribio is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A PB ratio of 1.22 means the investor is paying ¥1.22 for each ¥1 in book value.

Let's take a look of the Price to Book Ratio trends of Guangdong Hybribio Biotech Co Ltd:

  • The EOD is 0.788. Based on the equity, the company is cheap. +2
  • The MRQ is 1.223. Based on the equity, the company is underpriced. +1
  • The TTM is 1.674. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.788MRQ1.223-0.436
MRQ1.223TTM1.674-0.450
TTM1.674YOY4.028-2.355
TTM1.6745Y7.911-6.237
5Y7.91110Y7.9110.000
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD0.7881.946-1.158
MRQ1.2232.228-1.005
TTM1.6742.168-0.494
YOY4.0283.002+1.026
5Y7.9113.517+4.394
10Y7.9114.125+3.786
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Guangdong Hybribio Biotech Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0260.018+50%0.737-96%0.418-94%0.418-94%
Book Value Per Share--7.9458.015-1%6.607+20%4.774+66%4.774+66%
Current Ratio--4.5683.950+16%3.370+36%4.960-8%4.960-8%
Debt To Asset Ratio--0.1540.183-16%0.206-25%0.153+1%0.153+1%
Debt To Equity Ratio--0.1920.238-19%0.284-32%0.199-4%0.199-4%
Dividend Per Share--0.0010.060-98%0.046-97%0.031-96%0.031-96%
Eps--0.0760.158-52%0.655-88%0.265-71%0.265-71%
Free Cash Flow Per Share--0.0690.076-9%0.139-50%0.030+129%0.030+129%
Free Cash Flow To Equity Per Share--0.069-0.017+125%0.031+122%0.080-13%0.080-13%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--3.613--------
Intrinsic Value_10Y_min--3.082--------
Intrinsic Value_1Y_max--0.249--------
Intrinsic Value_1Y_min--0.245--------
Intrinsic Value_3Y_max--0.835--------
Intrinsic Value_3Y_min--0.795--------
Intrinsic Value_5Y_max--1.524--------
Intrinsic Value_5Y_min--1.407--------
Market Cap4047096209.920-56%6309736775.2808708510575.070-28%16427606369.245-62%16789337451.287-62%16789337451.287-62%
Net Profit Margin--0.2020.196+3%0.338-40%0.257-21%0.257-21%
Operating Margin---0.162-100%0.442-100%0.300-100%0.300-100%
Operating Ratio--1.5461.168+32%0.845+83%0.972+59%0.972+59%
Pb Ratio0.788-55%1.2231.674-27%4.028-70%7.911-85%7.911-85%
Pe Ratio20.624-55%32.02328.587+12%11.690+174%55.331-42%55.331-42%
Price Per Share6.260-55%9.72013.450-28%25.410-62%25.965-63%25.965-63%
Price To Free Cash Flow Ratio22.656-55%35.179-1.763+105%-4.971+114%-459.624+1407%-459.624+1407%
Price To Total Gains Ratio225.915-55%350.782319.076+10%36.175+870%-2106.678+701%-2106.678+701%
Quick Ratio--3.2112.803+15%2.506+28%2.967+8%2.967+8%
Return On Assets--0.0080.016-49%0.077-90%0.044-82%0.044-82%
Return On Equity--0.0100.021-52%0.106-91%0.058-83%0.058-83%
Total Gains Per Share--0.0280.077-64%0.783-96%0.449-94%0.449-94%
Usd Book Value--712228119.249717047613.598-1%589861213.382+21%426548806.390+67%426548806.390+67%
Usd Book Value Change Per Share--0.0040.002+50%0.102-96%0.058-94%0.058-94%
Usd Book Value Per Share--1.0971.107-1%0.912+20%0.659+66%0.659+66%
Usd Dividend Per Share--0.0000.008-98%0.006-97%0.004-96%0.004-96%
Usd Eps--0.0100.022-52%0.090-88%0.037-71%0.037-71%
Usd Free Cash Flow--6192497.2496746976.363-8%12439961.711-50%2690562.331+130%2690562.331+130%
Usd Free Cash Flow Per Share--0.0100.010-9%0.019-50%0.004+129%0.004+129%
Usd Free Cash Flow To Equity Per Share--0.010-0.002+125%0.004+122%0.011-13%0.011-13%
Usd Market Cap558903986.590-56%871374648.6661202645310.417-28%2268652439.593-62%2318607502.023-62%2318607502.023-62%
Usd Price Per Share0.865-55%1.3421.857-28%3.509-62%3.586-63%3.586-63%
Usd Profit--6802827.85414134301.544-52%58464869.605-88%23692694.677-71%23692694.677-71%
Usd Revenue--33695565.56475575779.951-55%170552294.398-80%81439114.404-59%81439114.404-59%
Usd Total Gains Per Share--0.0040.011-64%0.108-96%0.062-94%0.062-94%
 EOD+4 -4MRQTTM+12 -23YOY+12 -235Y+12 -2310Y+12 -23

3.2. Fundamental Score

Let's check the fundamental score of Guangdong Hybribio Biotech Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1520.624
Price to Book Ratio (EOD)Between0-10.788
Net Profit Margin (MRQ)Greater than00.202
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.211
Current Ratio (MRQ)Greater than14.568
Debt to Asset Ratio (MRQ)Less than10.154
Debt to Equity Ratio (MRQ)Less than10.192
Return on Equity (MRQ)Greater than0.150.010
Return on Assets (MRQ)Greater than0.050.008
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of Guangdong Hybribio Biotech Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.805
Ma 20Greater thanMa 506.542
Ma 50Greater thanMa 1006.983
Ma 100Greater thanMa 2007.806
OpenGreater thanClose6.280
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-09-302022-12-312023-03-312023-06-302023-09-30
Operating Income  727,337-58,533668,804-645,33823,46657,72481,190-99,684-18,494



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in CNY. All numbers in thousands.

Summary
Total Assets6,095,144
Total Liabilities937,808
Total Stockholder Equity4,883,453
 As reported
Total Liabilities 937,808
Total Stockholder Equity+ 4,883,453
Total Assets = 6,095,144

Assets

Total Assets6,095,144
Total Current Assets3,604,906
Long-term Assets2,490,238
Total Current Assets
Cash And Cash Equivalents 788,455
Short-term Investments 277,048
Net Receivables 2,257,002
Inventory 120,774
Other Current Assets 118,543
Total Current Assets  (as reported)3,604,906
Total Current Assets  (calculated)3,561,821
+/- 43,085
Long-term Assets
Property Plant Equipment 1,428,846
Intangible Assets 276,219
Long-term Assets Other 19,921
Long-term Assets  (as reported)2,490,238
Long-term Assets  (calculated)1,724,986
+/- 765,252

Liabilities & Shareholders' Equity

Total Current Liabilities789,091
Long-term Liabilities148,716
Total Stockholder Equity4,883,453
Total Current Liabilities
Short Long Term Debt 66,390
Accounts payable 168,677
Other Current Liabilities 899
Total Current Liabilities  (as reported)789,091
Total Current Liabilities  (calculated)235,966
+/- 553,125
Long-term Liabilities
Long term Debt 20,013
Capital Lease Obligations Min Short Term Debt24,821
Long-term Liabilities  (as reported)148,716
Long-term Liabilities  (calculated)44,834
+/- 103,883
Total Stockholder Equity
Retained Earnings 3,212,706
Total Stockholder Equity (as reported)4,883,453
Total Stockholder Equity (calculated)3,212,706
+/- 1,670,747
Other
Capital Stock649,150
Common Stock Shares Outstanding 649,150
Net Invested Capital 4,969,856
Net Working Capital 2,815,814
Property Plant and Equipment Gross 1,428,846



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
1,189,071
1,191,343
1,239,664
1,296,968
1,381,029
1,545,560
2,739,214
2,856,964
3,229,179
3,544,165
3,947,055
4,231,385
5,137,518
5,799,933
6,399,773
6,731,126
6,441,765
6,170,051
6,095,144
6,095,1446,170,0516,441,7656,731,1266,399,7735,799,9335,137,5184,231,3853,947,0553,544,1653,229,1792,856,9642,739,2141,545,5601,381,0291,296,9681,239,6641,191,3431,189,071
   > Total Current Assets 
701,196
679,696
644,448
664,630
747,512
884,941
2,039,002
1,962,126
2,222,912
2,383,501
2,626,025
2,552,467
3,328,726
3,679,345
4,137,738
4,400,278
4,023,150
3,729,307
3,604,906
3,604,9063,729,3074,023,1504,400,2784,137,7383,679,3453,328,7262,552,4672,626,0252,383,5012,222,9121,962,1262,039,002884,941747,512664,630644,448679,696701,196
       Cash And Cash Equivalents 
67,394
60,927
49,132
257,333
301,068
102,131
1,170,440
390,958
403,693
289,090
557,856
521,973
484,282
582,572
664,017
1,024,776
932,451
775,747
788,455
788,455775,747932,4511,024,776664,017582,572484,282521,973557,856289,090403,693390,9581,170,440102,131301,068257,33349,13260,92767,394
       Short-term Investments 
0
0
0
5,000
0
189,000
170,000
860,000
713,000
720,800
676,300
677,144
562,963
476,282
387,664
387,057
373,104
265,301
277,048
277,048265,301373,104387,057387,664476,282562,963677,144676,300720,800713,000860,000170,000189,00005,000000
       Net Receivables 
271,432
294,370
315,715
344,716
367,619
490,365
575,407
586,427
849,545
1,143,861
1,139,291
1,130,887
1,938,607
2,313,185
2,764,715
2,741,722
2,456,940
2,426,980
2,257,002
2,257,0022,426,9802,456,9402,741,7222,764,7152,313,1851,938,6071,130,8871,139,2911,143,861849,545586,427575,407490,365367,619344,716315,715294,370271,432
       Inventory 
46,886
50,011
53,117
43,414
60,235
78,408
99,882
96,305
183,197
179,229
183,473
147,143
221,505
220,184
213,387
118,739
107,684
121,430
120,774
120,774121,430107,684118,739213,387220,184221,505147,143183,473179,229183,19796,30599,88278,40860,23543,41453,11750,01146,886
       Other Current Assets 
300,590
257,255
207,515
9,601
11,240
13,097
12,788
16,425
27,335
31,164
40,133
51,947
61,854
66,542
73,382
93,148
152,972
121,603
118,543
118,543121,603152,97293,14873,38266,54261,85451,94740,13331,16427,33516,42512,78813,09711,2409,601207,515257,255300,590
   > Long-term Assets 
487,875
511,647
595,216
632,338
633,517
660,619
700,213
894,838
1,006,267
1,160,664
1,321,030
1,678,918
1,808,792
2,120,588
2,262,035
2,330,848
2,418,615
2,440,745
2,490,238
2,490,2382,440,7452,418,6152,330,8482,262,0352,120,5881,808,7921,678,9181,321,0301,160,6641,006,267894,838700,213660,619633,517632,338595,216511,647487,875
       Property Plant Equipment 
371,843
382,224
389,197
413,401
418,126
426,510
444,372
598,453
682,744
780,051
929,009
1,167,564
1,278,773
1,375,787
1,434,325
1,316,959
1,382,360
1,403,450
1,428,846
1,428,8461,403,4501,382,3601,316,9591,434,3251,375,7871,278,7731,167,564929,009780,051682,744598,453444,372426,510418,126413,401389,197382,224371,843
       Intangible Assets 
30,956
20,273
105,171
104,583
104,074
113,703
113,894
118,764
121,949
123,442
124,173
124,712
125,921
128,549
222,067
218,767
271,316
274,555
276,219
276,219274,555271,316218,767222,067128,549125,921124,712124,173123,442121,949118,764113,894113,703104,074104,583105,17120,27330,956
       Other Assets 
80,796
91,544
97,172
108,327
106,499
120,125
143,581
119,692
117,278
162,492
176,560
137,404
158,049
197,691
169,573
0
273,245
266,173
0
0266,173273,2450169,573197,691158,049137,404176,560162,492117,278119,692143,581120,125106,499108,32797,17291,54480,796
> Total Liabilities 
94,419
96,903
96,074
112,328
165,039
244,335
252,156
322,686
490,365
692,022
762,660
756,373
1,109,348
1,308,932
1,308,911
1,504,242
1,197,235
1,029,863
937,808
937,8081,029,8631,197,2351,504,2421,308,9111,308,9321,109,348756,373762,660692,022490,365322,686252,156244,335165,039112,32896,07496,90394,419
   > Total Current Liabilities 
83,407
86,449
86,337
106,217
159,541
239,435
247,869
303,022
470,873
666,583
731,917
677,586
1,022,575
1,207,462
1,212,951
1,362,832
1,060,390
886,331
789,091
789,091886,3311,060,3901,362,8321,212,9511,207,4621,022,575677,586731,917666,583470,873303,022247,869239,435159,541106,21786,33786,44983,407
       Short Long Term Debt 
0
0
0
0
81,272
81,272
75,272
75,272
97,000
180,000
246,458
151,500
53,453
167,328
63,730
98,484
100,181
100,107
66,390
66,390100,107100,18198,48463,730167,32853,453151,500246,458180,00097,00075,27275,27281,27281,2720000
       Accounts payable 
27,161
27,317
25,611
35,922
31,737
44,016
50,434
86,200
188,520
232,589
183,073
221,147
451,692
336,398
347,459
466,690
335,377
251,131
168,677
168,677251,131335,377466,690347,459336,398451,692221,147183,073232,589188,52086,20050,43444,01631,73735,92225,61127,31727,161
       Other Current Liabilities 
0
0
42,916
30,901
33,227
53,518
95,456
45,372
135,017
108,487
200,605
123,187
367,599
251,922
576,888
387,321
515,934
301,179
899
899301,179515,934387,321576,888251,922367,599123,187200,605108,487135,01745,37295,45653,51833,22730,90142,91600
   > Long-term Liabilities 
11,012
10,454
9,737
6,111
5,497
4,900
4,288
19,664
19,492
25,439
30,743
78,786
86,773
101,470
95,959
141,410
136,845
143,532
148,716
148,716143,532136,845141,41095,959101,47086,77378,78630,74325,43919,49219,6644,2884,9005,4976,1119,73710,45411,012
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
5,933
11,358
26,862
25,456
35,957
23,069
30,535
28,309
27,365
24,821
24,82127,36528,30930,53523,06935,95725,45626,86211,3585,933000000000
       Other Liabilities 
10,879
10,229
9,522
5,879
5,284
4,689
4,092
19,497
19,339
19,355
19,267
51,924
61,317
65,513
72,890
0
108,536
106,158
0
0106,158108,536072,89065,51361,31751,92419,26719,35519,33919,4974,0924,6895,2845,8799,52210,22910,879
> Total Stockholder Equity
983,345
983,962
1,037,914
1,081,718
1,103,527
1,174,680
2,348,192
2,390,534
2,580,980
2,654,878
2,934,746
3,194,385
3,695,550
4,111,050
4,677,441
4,906,567
4,943,110
4,848,037
4,883,453
4,883,4534,848,0374,943,1104,906,5674,677,4414,111,0503,695,5503,194,3852,934,7462,654,8782,580,9802,390,5342,348,1921,174,6801,103,5271,081,7181,037,914983,962983,345
   Common Stock
182,008
217,424
217,381
217,381
212,454
212,454
235,382
235,382
235,382
293,894
293,894
293,894
293,894
439,516
439,516
0
439,516
649,150
0
0649,150439,5160439,516439,516293,894293,894293,894293,894235,382235,382235,382212,454212,454217,381217,381217,424182,008
   Retained Earnings 
411,248
409,771
454,912
531,132
550,871
617,626
761,962
851,331
1,023,271
1,183,840
1,439,742
1,633,667
2,133,392
2,510,043
3,019,900
3,200,518
3,322,544
3,226,106
3,212,706
3,212,7063,226,1063,322,5443,200,5183,019,9002,510,0432,133,3921,633,6671,439,7421,183,8401,023,271851,331761,962617,626550,871531,132454,912409,771411,248
   Accumulated Other Comprehensive Income 0000000000000000000
   Capital Surplus 0000000000000000000
   Treasury Stock0000000000000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue2,189,016
Cost of Revenue-690,621
Gross Profit1,498,3951,498,395
 
Operating Income (+$)
Gross Profit1,498,395
Operating Expense-1,434,050
Operating Income754,96664,345
 
Operating Expense (+$)
Research Development190,073
Selling General Administrative309,326
Selling And Marketing Expenses-
Operating Expense1,434,050499,399
 
Net Interest Income (+$)
Interest Income5,589
Interest Expense-7,952
Other Finance Cost-46,650
Net Interest Income44,287
 
Pretax Income (+$)
Operating Income754,966
Net Interest Income44,287
Other Non-Operating Income Expenses-
Income Before Tax (EBT)310,108754,966
EBIT - interestExpense = -7,952
409,393
417,345
Interest Expense7,952
Earnings Before Interest and Taxes (EBIT)-318,060
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax310,108
Tax Provision-2,994
Net Income From Continuing Ops307,114307,114
Net Income409,393
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--44,287
 

Technical Analysis of Hybribio
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Hybribio. The general trend of Hybribio is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Hybribio's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Guangdong Hybribio Biotech Co Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 6.81 < 7.43 < 7.81.

The bearish price targets are: 5.65.

Tweet this
Guangdong Hybribio Biotech Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Guangdong Hybribio Biotech Co Ltd. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Guangdong Hybribio Biotech Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Guangdong Hybribio Biotech Co Ltd. The current macd is -0.28417152.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Hybribio price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Hybribio. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Hybribio price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Guangdong Hybribio Biotech Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartGuangdong Hybribio Biotech Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Guangdong Hybribio Biotech Co Ltd. The current adx is 32.12.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Hybribio shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Guangdong Hybribio Biotech Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Guangdong Hybribio Biotech Co Ltd. The current sar is 5.791.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Guangdong Hybribio Biotech Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Guangdong Hybribio Biotech Co Ltd. The current rsi is 41.81. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Guangdong Hybribio Biotech Co Ltd Daily Relative Strength Index (RSI) ChartGuangdong Hybribio Biotech Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Guangdong Hybribio Biotech Co Ltd. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Hybribio price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Guangdong Hybribio Biotech Co Ltd Daily Stochastic Oscillator ChartGuangdong Hybribio Biotech Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Guangdong Hybribio Biotech Co Ltd. The current cci is -46.45615071.

Guangdong Hybribio Biotech Co Ltd Daily Commodity Channel Index (CCI) ChartGuangdong Hybribio Biotech Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Guangdong Hybribio Biotech Co Ltd. The current cmo is -11.20966596.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Guangdong Hybribio Biotech Co Ltd Daily Chande Momentum Oscillator (CMO) ChartGuangdong Hybribio Biotech Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Guangdong Hybribio Biotech Co Ltd. The current willr is -63.35877863.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Hybribio is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Guangdong Hybribio Biotech Co Ltd Daily Williams %R ChartGuangdong Hybribio Biotech Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Guangdong Hybribio Biotech Co Ltd.

Guangdong Hybribio Biotech Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Guangdong Hybribio Biotech Co Ltd. The current atr is 0.26020484.

Guangdong Hybribio Biotech Co Ltd Daily Average True Range (ATR) ChartGuangdong Hybribio Biotech Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Guangdong Hybribio Biotech Co Ltd. The current obv is 185,146,289.

Guangdong Hybribio Biotech Co Ltd Daily On-Balance Volume (OBV) ChartGuangdong Hybribio Biotech Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Guangdong Hybribio Biotech Co Ltd. The current mfi is 43.62.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Guangdong Hybribio Biotech Co Ltd Daily Money Flow Index (MFI) ChartGuangdong Hybribio Biotech Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Guangdong Hybribio Biotech Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-26MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-31ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-25MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.

6.3. Candlestick Patterns

Guangdong Hybribio Biotech Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Guangdong Hybribio Biotech Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.805
Ma 20Greater thanMa 506.542
Ma 50Greater thanMa 1006.983
Ma 100Greater thanMa 2007.806
OpenGreater thanClose6.280
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Hybribio with someone you think should read this too:
  • Are you bullish or bearish on Hybribio? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Hybribio? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Guangdong Hybribio Biotech Co Ltd

I send you an email if I find something interesting about Guangdong Hybribio Biotech Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Guangdong Hybribio Biotech Co Ltd.

Receive notifications about Guangdong Hybribio Biotech Co Ltd in your mailbox!